

Author's Accepted Manuscript

An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer

T.L. Tammela , M. Häggman , S. Ladjevardi , K. Taari , T. Isotalo , H. Lennernäs , J. Weis , C. von Below , C. Wassberg , B. Lennernäs , A. Tolf , N. Axén , C.-G. Gölander , H. Ahlström



PII: S0022-5347(17)77188-1
DOI: [10.1016/j.juro.2017.07.072](https://doi.org/10.1016/j.juro.2017.07.072)
Reference: JURO 14882

To appear in: *The Journal of Urology*
Accepted Date: 1 July 2017

Please cite this article as: Tammela TL, Häggman M, Ladjevardi S, Taari K, Isotalo T, Lennernäs H, Weis J, von Below C, Wassberg C, Lennernäs B, Tolf A, Axén N, Gölander CG, Ahlström H, An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer, *The Journal of Urology*® (2017), doi: 10.1016/j.juro.2017.07.072.

DISCLAIMER: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our subscribers we are providing this early version of the article. The paper will be copy edited and typeset, and proof will be reviewed before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to The Journal pertain.

Embargo Policy

All article content is under embargo until uncorrected proof of the article becomes available online.

We will provide journalists and editors with full-text copies of the articles in question prior to the embargo date so that stories can be adequately researched and written. The standard embargo time is 12:01 AM ET on that date. Questions regarding embargo should be directed to jumedia@elsevier.com.

**AN INTRAPROSTATIC MODIFIED RELEASE FORMULATION OF
ANTIANDROGEN 2-HYDROXYFLUTAMIDE FOR LOCALIZED PROSTATE
CANCER**

¹Tammela T.L., ²Häggman M., ²Ladjevardi S., ³Taari K., ⁴Isotalo T., ⁵Lenneräs H., ⁶Weis J.,
⁶von Below C., ⁶Wassberg C., ⁷Lenneräs B., ⁸Tolf A., ⁹Axén N., ⁹Gölander C.-G., ⁶Ahlström
H.

¹Dept. of Urology, Tampere University Hospital (and University of Tampere) FIN-33520,
Tampere, Finland

²Dept. of Urology, Uppsala University Hospital, SE-751 85, Uppsala, Sweden

³Dept. of Urology, Helsinki University Hospital, FIN-00100, Helsinki, Finland

⁴Dept. of Urology, Päijät-Häme Central Hospital, FIN-15101, Lahti, Finland

⁵Dept. of Pharmacy, Uppsala University, SE-751 23, Uppsala, Sweden

⁶Dept. of Surgical Sciences, Radiology, Uppsala University Hospital, SE-75185, Uppsala,
Sweden

⁷Dept. of Oncology, University of Örebro, SE-701 82, Örebro, Sweden

⁸Dept. of Immunology, Genetics, and Pathology, Uppsala University, SE-751 85, Uppsala,
Sweden

⁹LIDDS AB, Virdings allé 32B, SE-754 50, Uppsala, Sweden

Corresponding Author: Professor Håkan Ahlström

E-mail: hakan.ahlstrom@radiol.uu.se

Telephone: +46-18-6114771

Download English Version:

<https://daneshyari.com/en/article/8771953>

Download Persian Version:

<https://daneshyari.com/article/8771953>

[Daneshyari.com](https://daneshyari.com)